PATENT CLAIM ANALYSIS

Application Number: 16008686
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["530", "351000"]

Abstract:
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.

Claim (Index 18):
The method of  claim 17 , wherein the fusion protein further comprises a linker connecting the interferon antagonist and the VHH or VNAR.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.58333
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14905348', '15642989', '15717205', '15278854', '14372730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7205978093818862
- 35 USC 102 Novelty (BERT): 0.5550079211740007
- Combined Prediction Score: 0.7040388205610977
- Mean Citation Score: 336.065532
- Max Citation Score: 458.25555
- Similarity Product: 307.5435305193097

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test